Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis. A pilot study
- 6 August 2022
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 67, 104094
Abstract
No abstract availableKeywords
Funding Information
- Genentech
This publication has 33 references indexed in Scilit:
- No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFITNeurology, 2015
- Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosisNeurology, 2015
- Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field modelNeuroImage, 2014
- Brief International Cognitive Assessment for MS (BICAMS): international standards for validationBMC Neurology, 2012
- The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosisHuman Brain Mapping, 2011
- Rituximab Treatment for Epstein-Barr Virus DNAemia after Alternative-Donor Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2011
- A Bayesian model of shape and appearance for subcortical brain segmentationNeuroImage, 2011
- Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cordJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathologyBrain, 2006
- The Fatigue Severity ScaleArchives of Neurology, 1989